Fabino Enter (543444)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales grew 56%, showing strong recent topline momentum.
• Latest quarter revenue of ₹7 Cr against a ₹6 Cr market cap implies a very low price-to-sales multiple if business stabilizes.
• ROCE is positive at 5.61%, indicating some return from capital employed.
• Stock is trading near the top of its 52-week range of ₹13.10-₹28.27, reflecting market interest.

Concerns

• Net profit growth is -733.33%, and latest quarter net profit is ₹-0 Cr, so there are no real earnings.
• P/E is 0.00 and book value/P/B are unavailable, leaving no margin-of-safety metrics.
• Piotroski F-Score is only 4/9, signalling weak overall financial health.
• No dividend and no promoter holding disclosure reduce confidence in governance and alignment.

AI Analysis

Looking at Fabino Enter, my first reaction is to turn the page. Price ₹28.27, market cap just ₹6 Cr, P/E 0.00, book value not available. A Graham investor refuses to pay for absent earnings. The company shows 56% sales growth and latest quarter sales of ₹7 Cr, which against a ₹6 Cr market cap creates a very low revenue multiple. But revenue without profit is not value. Profit growth is -733.33%; latest quarter net profit is ₹-0 Cr. That is not a franchise; it is a promise. ROCE at 5.61% is below what a small pharma manufacturer needs to compensate for risk. Piotroski F-Score 4/9 suggests weak financial health. No dividend, no promoter holding data—so I cannot judge alignment. The 52-week range ₹13.10-₹28.27 shows the stock has doubled, but price action is not investment analysis. In Buffett's terms, this is a cigar butt with only a few puffs, and the wet wrapper of negative earnings makes me doubt even that. If sales growth continues and margins normalize, it could be an interesting turnaround. But I need book value, debt levels, cash flows, and proof that rupee sales can become rupee profits. Until then, this is a trading vehicle, not a Graham-Buffett compounder. My circle of competence says wait; the figures do not offer margin of safety.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer